|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: MRPS22 |
Gene summary for MRPS22 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | MRPS22 | Gene ID | 56945 |
| Gene name | mitochondrial ribosomal protein S22 | |
| Gene Alias | C3orf5 | |
| Cytomap | 3q23 | |
| Gene Type | protein-coding | GO ID | GO:0008150 | UniProtAcc | P82650 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 56945 | MRPS22 | LZE2T | Human | Esophagus | ESCC | 5.30e-08 | 9.33e-01 | 0.082 |
| 56945 | MRPS22 | LZE4T | Human | Esophagus | ESCC | 1.02e-14 | 3.48e-01 | 0.0811 |
| 56945 | MRPS22 | LZE5T | Human | Esophagus | ESCC | 2.34e-02 | 2.55e-01 | 0.0514 |
| 56945 | MRPS22 | LZE7T | Human | Esophagus | ESCC | 6.99e-08 | 4.72e-01 | 0.0667 |
| 56945 | MRPS22 | LZE8T | Human | Esophagus | ESCC | 7.64e-07 | 3.00e-01 | 0.067 |
| 56945 | MRPS22 | LZE20T | Human | Esophagus | ESCC | 5.99e-05 | 1.88e-01 | 0.0662 |
| 56945 | MRPS22 | LZE22T | Human | Esophagus | ESCC | 1.08e-07 | 3.32e-01 | 0.068 |
| 56945 | MRPS22 | LZE24T | Human | Esophagus | ESCC | 6.19e-22 | 5.69e-01 | 0.0596 |
| 56945 | MRPS22 | LZE6T | Human | Esophagus | ESCC | 7.59e-06 | 3.44e-01 | 0.0845 |
| 56945 | MRPS22 | P1T-E | Human | Esophagus | ESCC | 3.91e-08 | 4.94e-01 | 0.0875 |
| 56945 | MRPS22 | P2T-E | Human | Esophagus | ESCC | 9.09e-53 | 1.07e+00 | 0.1177 |
| 56945 | MRPS22 | P4T-E | Human | Esophagus | ESCC | 1.15e-48 | 1.19e+00 | 0.1323 |
| 56945 | MRPS22 | P5T-E | Human | Esophagus | ESCC | 2.27e-46 | 9.24e-01 | 0.1327 |
| 56945 | MRPS22 | P8T-E | Human | Esophagus | ESCC | 1.55e-38 | 7.03e-01 | 0.0889 |
| 56945 | MRPS22 | P9T-E | Human | Esophagus | ESCC | 3.31e-25 | 6.35e-01 | 0.1131 |
| 56945 | MRPS22 | P10T-E | Human | Esophagus | ESCC | 2.14e-37 | 7.06e-01 | 0.116 |
| 56945 | MRPS22 | P11T-E | Human | Esophagus | ESCC | 1.20e-17 | 6.44e-01 | 0.1426 |
| 56945 | MRPS22 | P12T-E | Human | Esophagus | ESCC | 6.40e-32 | 5.77e-01 | 0.1122 |
| 56945 | MRPS22 | P15T-E | Human | Esophagus | ESCC | 2.36e-43 | 8.56e-01 | 0.1149 |
| 56945 | MRPS22 | P16T-E | Human | Esophagus | ESCC | 2.71e-39 | 6.83e-01 | 0.1153 |
| Page: 1 2 3 4 5 6 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| MRPS22 | SNV | Missense_Mutation | c.808G>C | p.Gly270Arg | p.G270R | P82650 | protein_coding | deleterious(0.01) | probably_damaging(0.999) | TCGA-A2-A0EQ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD | |
| MRPS22 | SNV | Missense_Mutation | c.619N>G | p.Pro207Ala | p.P207A | P82650 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-A8-A09A-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD | |
| MRPS22 | SNV | Missense_Mutation | novel | c.107T>C | p.Leu36Pro | p.L36P | P82650 | protein_coding | deleterious_low_confidence(0.03) | benign(0.003) | TCGA-B6-A40B-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| MRPS22 | SNV | Missense_Mutation | c.913N>G | p.His305Asp | p.H305D | P82650 | protein_coding | deleterious(0.04) | possibly_damaging(0.897) | TCGA-BH-A18V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| MRPS22 | SNV | Missense_Mutation | c.217N>A | p.Glu73Lys | p.E73K | P82650 | protein_coding | tolerated(0.16) | benign(0.017) | TCGA-C5-A1MH-01 | Cervix | cervical & endocervical cancer | Female | >=65 | III/IV | Chemotherapy | cisplatin | PD | |
| MRPS22 | SNV | Missense_Mutation | novel | c.28C>A | p.Leu10Met | p.L10M | P82650 | protein_coding | deleterious_low_confidence(0.03) | benign(0.01) | TCGA-EA-A3HS-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
| MRPS22 | SNV | Missense_Mutation | c.132N>G | p.Phe44Leu | p.F44L | P82650 | protein_coding | tolerated_low_confidence(0.81) | benign(0) | TCGA-EK-A2RO-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
| MRPS22 | SNV | Missense_Mutation | novel | c.562N>A | p.Glu188Lys | p.E188K | P82650 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-VS-A954-01 | Cervix | cervical & endocervical cancer | Female | >=65 | III/IV | Chemotherapy | cisplatin | CR |
| MRPS22 | SNV | Missense_Mutation | rs773327850 | c.976N>C | p.Asn326His | p.N326H | P82650 | protein_coding | tolerated(0.14) | benign(0.001) | TCGA-AA-3977-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
| MRPS22 | SNV | Missense_Mutation | rs755925113 | c.1064G>A | p.Arg355His | p.R355H | P82650 | protein_coding | deleterious(0.01) | benign(0.042) | TCGA-DM-A282-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |